Ban diabetes drug Avandia: consumer group to FDA
Last Updated: Friday, October 31, 2008 | 1:18 PM ET
CBC News
Related
Internal Links
External Links
(Note: CBC does not endorse and is not responsible for the content of external sites - links will open in new window)
The diabetes drug Avandia should be banned over its risks of heart and liver damage, a U.S. consumer group urged.
In a petition filed with the U.S. Food and Drug Administration on Thursday, the group Public Citizen called for the Type 2 diabetes drug, whose generic name is rosiglitazone, to be pulled from the market.
Last week, the American Diabetes Association and a European counterpart unanimously advised doctors against using Avandia in updated treatment guidelines.
"The FDA is in possession of clear, unequivocal evidence that (Avandia) causes a wide variety of toxicities," Public Citizen said in its petition.
"Many of these are life-threatening, such as heart attacks, heart failure (and) liver failure."
In November 2007, GlaxoSmithKline Inc., the manufacturer of rosiglitazone, updated its prescribing information in consultation with Health Canada after a study published in the New England Journal of Medicine reported a 43 per cent higher risk of heart attack for those taking rosiglitazone compared to people taking other diabetes drugs or no diabetes medication at all.
Public Citizen said its has identified 14 cases of liver failure linked to Avandia, including 12 deaths, based on its analysis of suspected adverse drug reactions sent to the FDA.
"In addition there is clear previous evidence of increased risk of heart attacks, heart failure, bone fractures, anemia and macular (retinal) edema with vision loss," the petition said.
Safer, more effective drugs for Type 2 diabetes include metformin (sold in Canada under the brand names Glucophag Glumetza or in generic forms with "metformin" as part of the name) and glipizide (brand name Glucotrol), Public Citizen said.
"We do not believe there is a connection between liver toxicity and this medicine," the company said in a statement.
In the statement, Glaxo said it does not believe Avandia causes liver failure and that a review by an independent panel earlier this year said the liver risks were acceptable.
The company added heart attack data is inconclusive and that Avandia is safe and effective, when used as directed.
There was no immediate response from the FDA.
With files from the Associated Press and ReutersShare Tools
Top News Headlines
- Outrage grows over Syria killings
- The deaths in Syria of over 90 people, including at least 32 children, has sparked international outrage and raised fears that the international peace plan is in tatters. more »
- Montreal protesters march in peaceful defiance
- The clanging of pots and pans sounded throughout Montreal's downtown core Saturday night and into early Sunday morning, as thousands of protesters marched on in peaceful — but loud — defiance of Bill 78. more »
- Quebec tornadoes cause millions in damage
- Environment Canada confirms that two tornadoes — one of which was classed as a moderate F-1 packing winds of up to 150 km/h — touched down near Montreal Friday night, causing millions of dollars in damage. more »
- Teen struck by lightning in Ottawa dies
- The victim of a Friday lightning strike during a storm in east Ottawa has died, CBC News has learned. more »
- Teen struck by lightning in Ottawa dies
- Missing Winnipeg children found in Mexico
- Quebec tornadoes cause millions in damage
- Montreal protesters march in peaceful defiance
- Woman's remains found in hockey bag on Cape Breton river
- Outrage grows over Syria killings
- Pope's butler arrested in Vatican leaks scandal
- Everest team unable to bring down Toronto woman's body
- WWE apologizes to Brazil over Canadian's flag stomp
